These results suggest that ST6GAL1 plays a pivotal role in the CRC TME, where low expression of ST6GAL1 may be associated with CD8+ effector T cell infiltration, tertiary lymphoid structure, and M1 macrophage polarization, thus fostering an “immune‐activated” TME that potentially improves prognosis and may enhance the sensitivity to PD‐L1 immunotherapy. The gene discussed is CD8A; the disease is colorectal carcinoma.